Skip to main content

Vertex Pharmaceuticals CASGEVY revenue

  • VRTX · Nasdaq
  • Pharmaceuticals
  • Biotechnology
  • S&P 500
$538.60−0.74%Close 13 Nov 2026

CASGEVY revenue at Vertex Pharmaceuticals came to $99.2M for the quarter to 30 Sep 2026, up 487.0% from a year earlier.

As Vertex Pharmaceuticals reported it in its earnings release and quarterly or annual report, compiled and checked by AapWire. Latest figure filed 3 Nov 2026.

By quarter

$0Mar 2024$0Jun 2024$2.0MSep 2024$14.2MMar 2025$30.4MJun 2025$16.9MSep 2025$42.9MMar 2026$76.4MJun 2026$99.2MSep 2026
Vertex Pharmaceuticals CASGEVY revenue, every reported period
Period endingCASGEVY revenueChange on a yearFiled
30 Sep 2026$99.2Mup 487.0%3 Nov 2026
30 Jun 2026$76.4Mup 151.3%4 Aug 2026
31 Mar 2026$42.9Mup 202.1%5 May 2026
30 Sep 2025$16.9Mup 745.0%4 Nov 2025
30 Jun 2025$30.4M—5 Aug 2025
31 Mar 2025$14.2M—6 May 2025
30 Sep 2024$2.0M—5 Nov 2024
30 Jun 2024$0—2 Aug 2024
31 Mar 2024$0—7 May 2024

Definition

Revenue from this part of the business, as the company names and reports it in its results. Each figure is read from the table or sentence the company printed and kept with its scale and decimals; see data and methodology.

Other operating KPIs of Vertex Pharmaceuticals: Product revenues, net revenue · TRIKAFTA/KAFTRIO revenue · ALYFTREK revenue · JOURNAVX revenue · United States revenue · Europe revenue · financial statements

Every KPI and segment of VRTX, in the terminal.

Ten years of operating figures, segments, guidance against results, charts and alerts on each new release.